Xenetic Biosciences Company Leadership
| XBIO Stock | USD 3.37 0.03 0.88% |
Xenetic Biosciences employs about 4 people. The company is managed by 3 executives with a total tenure of roughly 16 years, averaging almost 5.0 years of service per executive, having 1.33 employees per reported executive. Analysis of Xenetic Biosciences' management performance can provide insight into the firm performance.
Xenetic |
Xenetic Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Xenetic Biosciences' future performance. Based on our forecasts, it is anticipated that Xenetic will maintain a workforce of about 8 employees by April 2025.Xenetic Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.3002) % which means that it has lost $0.3002 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5012) %, meaning that it created substantial loss on money invested by shareholders. Xenetic Biosciences' management efficiency ratios could be used to measure how well Xenetic Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of March 2025, Return On Tangible Assets is likely to drop to -0.6. In addition to that, Return On Capital Employed is likely to drop to -0.73. At this time, Xenetic Biosciences' Total Assets are very stable compared to the past year. As of the 23rd of March 2025, Total Current Assets is likely to grow to about 8.7 M, while Non Current Assets Total are likely to drop about 298.2 K.As of the 23rd of March 2025, Common Stock Shares Outstanding is likely to grow to about 1.6 M, while Net Loss is likely to drop (6.8 M).
Xenetic Biosciences Workforce Comparison
Xenetic Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,140. Xenetic Biosciences adds roughly 4.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Xenetic Biosciences Profit Margins
The company has Profit Margin (PM) of (1.58) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.69) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.69.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.77 | 0.89 |
|
|
Xenetic Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xenetic Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xenetic Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Xenetic Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-12-01 | 10.0 | 10 | 1 | 57,500 | 0.00 |
| 2019-09-01 | 3.0 | 3 | 1 | 143,390 | 0.00 |
| 2016-12-01 | 3.4545 | 38 | 11 | 1,195,000 | 1,825,760 |
Xenetic Biosciences Notable Stakeholders
A Xenetic Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Xenetic Biosciences often face trade-offs trying to please all of them. Xenetic Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Xenetic Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jeffrey Esq | President Director | Profile | |
| James Parslow | CFO, Principal Accounting Officer, Principal Financial Officer | Profile | |
| Curtis Lockshin | Chief Scientific Officer | Profile |
About Xenetic Biosciences Management Performance
The success or failure of an entity such as Xenetic Biosciences often depends on how effective the management is. Xenetic Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Xenetic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Xenetic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.57) | (0.60) | |
| Return On Capital Employed | (0.70) | (0.73) | |
| Return On Assets | (0.57) | (0.60) | |
| Return On Equity | (0.66) | (0.69) |
Xenetic Biosciences Workforce Analysis
Traditionally, organizations such as Xenetic Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Xenetic Biosciences within its industry.Xenetic Biosciences Manpower Efficiency
Return on Xenetic Biosciences Manpower
| Revenue Per Employee | 625.1K | |
| Revenue Per Executive | 833.4K | |
| Net Loss Per Employee | 990.1K | |
| Net Loss Per Executive | 1.3M | |
| Working Capital Per Employee | 1.4M | |
| Working Capital Per Executive | 1.9M |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.57) | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets | Return On Equity |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.